STOCK TITAN
  1. Home
  2. News
  3. PLRX

Pliant Therapeutics Inc - PLRX STOCK NEWS

Welcome to our dedicated news page for Pliant Therapeutics (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pliant Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pliant Therapeutics's position in the market.

News
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) reported positive interim data from the INTEGRIS-PSC trial of bexotegrast, demonstrating a favorable safety profile and encouraging antifibrotic activity in primary sclerosing cholangitis (PSC). The company also reported third quarter 2023 financial results, including research and development expenses of $32.3 million and a net loss of $41.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
earnings
-
News
Pliant Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Pliant Therapeutics, Inc. (PLRX) announced its participation in several investor conferences in November, including the Stifel 2023 Healthcare Conference, 6th Annual Evercore ISI HealthCONx Conference, and Piper Sandler 35th Annual Healthcare Conference. The company's President, CEO, and Chief Medical Officer will be part of fireside chats at these events. Interested parties can access live webcasts on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
conferences
-
News
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
Rhea-AI Summary
Pliant Therapeutics presented three posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The posters highlighted PLN-101095, a novel inhibitor of integrins αvβ8 and αvβ1. The drug showed promising results in inhibiting fibrotic markers and reducing tumor growth in preclinical models of pancreatic ductal adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.1%
Tags
none
News
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Rhea-AI Summary
Pliant Therapeutics, Inc. announced three presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The presentations will focus on the selective targeting of integrins αVβ8 and αVβ1 in pancreatic cancer, a phase 1a trial of PLN-101095 as monotherapy and in combination with pembrolizumab, and the expression of integrin αvβ1 in multiple solid tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Rhea-AI Summary
Pliant Therapeutics announces late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast at The Liver Meeting® 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
clinical trial
-
News
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Rhea-AI Summary
Pliant Therapeutics appoints Ms. S. Mishima Gerhart as Chief Regulatory Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.03%
Tags
management
News
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Rhea-AI Summary
Pliant Therapeutics announces positive data from Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. Bexotegrast was well tolerated over 12 weeks of treatment with no severe adverse events. Bexotegrast reduced Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses, with statistical significance at the 160 mg dose. Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12. Preliminary MRI imaging results suggest improved hepatocyte function and bile flow with bexotegrast 160 mg.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.33%
Tags
clinical trial
-
News
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Rhea-AI Summary
Pliant Therapeutics to discuss interim results from INTEGRIS-PSC Phase 2a trial in conference call and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.33%
Tags
conferences clinical trial
-
News
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
Rhea-AI Summary
Pliant Therapeutics appoints Minnie Kuo as Chief Development Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
management
News
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
Rhea-AI Summary
Pliant Therapeutics presents data at ERS International Congress, showcasing positive results from Phase 2a trial of bexotegrast in IPF patients. Bexotegrast at 320 mg well tolerated for up to 40 weeks with no discontinuations due to adverse events. Durable treatment effect on forced vital capacity observed. Proportion of bexotegrast-treated participants with stabilization or improvement of fibrosis was twice as high as placebo group. Bexotegrast reduces fibrogenesis in fibrotic human lung cells. Serum concentrations of integrin β6 significantly elevated in IPF patients and reduced following lung transplant. Analysis of integrin β6 as a biomarker may help characterize response to anti-fibrotic therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
Stock PLRX logo
Pliant Therapeutics Inc

Nasdaq:PLRX

PLRX Rankings

#2672 Ranked by Market Cap
#4556 Ranked by Stock Gains
N/A Ranked by Dividends

PLRX Stock Data

852.38M
47.09M
6.63%
111.28%
12.39%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
South San Francisco

About PLRX

pliant therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. by harnessing the therapeutic potential of integrin biology and tgf-β modulation, pliant aims to prevent or even reverse fibrosis to address the needs of many patients. the company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. pliant’s co-founders include world-renowned researchers from university of california, san francisco (ucsf), who bring broad experience in fibrosis biology and small molecule chemistry. together, the pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.